Kyowa Hakko Kogyo Co., Ltd.

Kyowa Hakko Koygo Co., Ltd.

Junichi Shimada

Fumio Suzuki

Hiromi Nonaka

Akio Ishii

Shunji Ichikawa

Shizuo Shiozaki

Akira Karasawa

Joji Nakamura

Nobuaki Koike

Tetsuji Ohno

Kazuhiro Kubo

Yoshihisa Kuwana

Shigeto Kitamura

Hiroshi Kase

Kenichi Mochida

Hideaki Kusaka

Tomoyuki Kanda

Kenji Ohmori

Ryo Okachi

Michio Ichimura

Takehiro Ogasa

Kiyoshi Sato

Nobuo Kosaka

Hiroshi Tsumuki

Hironori Imma

Masako Kurokawa

Ken Ikeda

Tohru Yasuzawa

Tadashi Hirata

Katsuichi Shuto

Yuzuru Matsuda

Takeshi Kuroda

Haruhiko Manabe

Satoshi Nakanishi

Yoshihisa Ohta

Takashi Kuwabara

Hiromasa Kato

Tamotsu Eguchi

Hiroshi Yano

Yuko Okamura

Mayumi Saki

Kotaro Takasaki

Naoto Osakada

Kazuihiro Kubo

Hideaki Mizumoto

Hiroshi Magara

Miho Suda

Shizuo Shioazaki

Chikako Katagiri

Toru Noji

Akiko Nakamura

Tadahi Hirata

Akira Horiguchi

The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administered.

Method of treating brain ischemia

Remedial agent for neural degeneration

&lsqb;1,2,4&rsqb;triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives

Remedies for diabetes

The present invention provides condensed purine derivatives or pharmacologically acceptable salts thereof exhibiting adenosine A,acceptor antagonising activity, and having an antiasthmatic action, a bronchodilator action, an antiantiitching action, etc., and represented by the following formula (I):

Condensed purine derivatives

&lsqb;1,2,4&rsqb;Triazolo&lsqb;1,5-c&rsqb;pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A,receptor antagonism and are useful for the treatment or prevention of various diseases induced by hyperactivity of adenosine A,receptors (for example, Parkinson's disease or senile dementia):

&lsqb;1,2,4&rsqb; triazolo &lsqb;1,5-C&rsqb; pyrimidine derivatives

Process for producing xanthine derivatives with bacteria and fungi

The present invention relates to a prophylactic agent or a therapeutic agent of pancreatitis, containing an adenosine uptake inhibitor or a pharmaceutically acceptable salt thereof.

Pancreatitis remedy

Method of treating depression with certain triazine derivatives

The present invention relates to novel xanthine derivatives of the formula (I) which are selectively antagonistic to an adenosine A.sub.2 receptor, and pharmaceutically acceptable salts thereof. Formula (I): ##STR1## In the formula, R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a propyl group, a butyl group or an allyl group; R.sup.3 represents a hydrogen atom or a lower alkyl group; Y.sup.1 and Y.sup.2 are the same or different and each represents a hydrogen atom or a methyl group; and Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a thienyl group.

Xanthine derivatives

Disclosed are xanthine derivatives represented by the following Formula (I): ##STR1## in which R.sup.1, R.sup.2, and R.sup.3 independently represent hydrogen or lower alkyl;

8-substituted styryl xanthine derivatives

Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.

Therapeutic agent for Parkinson's disease

Therapeutic purine agents for parkinson's disease

Antidepressants

Growing community of inventors

Shizuoka, Japan

Junichi Shimada